{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T20:42:19Z","timestamp":1763066539348,"version":"3.45.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-13207-9","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T20:37:21Z","timestamp":1763066241000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of umeclidinium\/vilanterol dual bronchodilator therapy on pulmonary function and inflammatory responses in stable COPD patients"],"prefix":"10.1038","volume":"15","author":[{"given":"Rongbin","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4700-4793","authenticated-orcid":false,"given":"Weijie","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyun","family":"Jian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiachun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"issue":"10342","key":"13207_CR1","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/S0140-6736(22)00470-6","volume":"399","author":"SA Christenson","year":"2022","unstructured":"Christenson, S. A., Smith, B. M., Bafadhel, M. & Putcha, N. Chronic obstructive pulmonary disease. Lancet 399 (10342), 2227\u20132242 (2022).","journal-title":"Lancet"},{"issue":"3","key":"13207_CR2","doi-asserted-by":"publisher","first-page":"ITC17","DOI":"10.7326\/AITC202008040","volume":"173","author":"WW Labaki","year":"2020","unstructured":"Labaki, W. W. & Rosenberg, S. R. Chronic obstructive pulmonary disease. Ann. Intern. Med. 173 (3), ITC17\u2013ITC32 (2020).","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"13207_CR3","doi-asserted-by":"publisher","first-page":"L64","DOI":"10.1152\/ajplung.00121.2021","volume":"322","author":"S Dey","year":"2022","unstructured":"Dey, S. et al. Pathogenesis, clinical features of asthma COPD overlap, and therapeutic modalities. Am. J. Physiology-Lung Cell. Mol. Physiol. 322 (1), L64\u2013L83 (2022).","journal-title":"Am. J. Physiology-Lung Cell. Mol. Physiol."},{"issue":"30","key":"13207_CR4","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1093\/eurheartj\/ehac268","volume":"43","author":"S Li","year":"2022","unstructured":"Li, S. et al. Modifiable risk factors associated with cardiovascular disease and mortality in china: a PURE substudy. Eur. Heart J. 43 (30), 2852\u20132863 (2022).","journal-title":"Eur. Heart J."},{"issue":"3","key":"13207_CR5","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ccm.2020.06.007","volume":"41","author":"AI Ritchie","year":"2020","unstructured":"Ritchie, A. I. & Wedzicha, J. A. Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations. Clin. Chest. Med. 41 (3), 421\u2013438 (2020).","journal-title":"Clin. Chest. Med."},{"issue":"18","key":"13207_CR6","doi-asserted-by":"publisher","first-page":"6924","DOI":"10.3390\/ijms21186924","volume":"21","author":"M Easter","year":"2020","unstructured":"Easter, M., Bollenbecker, S., Barnes, J. W. & Krick, S. Targeting aging pathways in chronic obstructive pulmonary disease. Int. J. Mol. Sci. 21 (18), 6924 (2020).","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"13207_CR7","first-page":"171","volume":"40","author":"P Pellicori","year":"2022","unstructured":"Pellicori, P., Cleland, J. G. F. & Clark, A. L. Chronic obstructive pulmonary disease and heart failure. Cardiol. Clin. 40 (2), 171\u2013182 (2022).","journal-title":"Cardiol. Clin."},{"issue":"6","key":"13207_CR8","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/resp.14041","volume":"26","author":"M MacLeod","year":"2021","unstructured":"MacLeod, M. et al. Chronic obstructive pulmonary disease exacerbation fundamentals: diagnosis, treatment, prevention and disease impact. Respirology 26 (6), 532\u2013551 (2021).","journal-title":"Respirology"},{"issue":"7","key":"13207_CR9","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/resp.14046","volume":"26","author":"D Singh","year":"2021","unstructured":"Singh, D. Pharmacological treatment of stable chronic obstructive pulmonary disease. Respirology 26 (7), 643\u2013651 (2021).","journal-title":"Respirology"},{"issue":"11","key":"13207_CR10","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1080\/17512433.2022.2134113","volume":"15","author":"MG Matera","year":"2022","unstructured":"Matera, M. G., Rinaldi, B., Belardo, C. & Cazzola, M. Pharmacotherapy of LAMA\/LABA inhaled therapy combinations for chronic obstructive pulmonary disease: a clinical overview. Expert Rev. Clin. Pharmacol. 15 (11), 1269\u20131281 (2022).","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"12","key":"13207_CR11","first-page":"1513","volume":"11","author":"Y Rosenwasser","year":"2022","unstructured":"Rosenwasser, Y., Berger, I. & Loewy, Z. G. Therapeutic approaches for chronic obstructive pulmonary disease (COPD) exacerbations. Pathogens (Basel Switzerland). 11 (12), 1513 (2022).","journal-title":"Pathogens (Basel Switzerland)"},{"issue":"15","key":"13207_CR12","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","volume":"359","author":"DP Tashkin","year":"2008","unstructured":"Tashkin, D. P. et al. A 4-Year trial of Tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 359 (15), 1543\u20131554 (2008).","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"13207_CR13","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1358\/dot.2002.38.9.696535","volume":"38","author":"PJB T.T H","year":"2002","unstructured":"T.T H, P. J. B. Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD. Drugs Today. 38 (9), 585 (2002).","journal-title":"Drugs Today"},{"issue":"1","key":"13207_CR14","first-page":"33","volume":"10","author":"JM Wells","year":"2023","unstructured":"Wells, J. M. et al. Mortality risk and serious cardiopulmonary events in Moderate-to-Severe COPD: post hoc analysis of the IMPACT trial. Chronic Obstr. Pulm Dis. 10 (1), 33\u201345 (2023).","journal-title":"Chronic Obstr. Pulm Dis."},{"issue":"10","key":"13207_CR15","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1513\/AnnalsATS.202001-023OC","volume":"17","author":"MJ Mammen","year":"2020","unstructured":"Mammen, M. J. et al. Triple therapy versus dual or monotherapy with Long-Acting bronchodilators for chronic obstructive pulmonary disease. A systematic review and Meta-analysis. Ann. Am. Thorac. Soc. 17 (10), 1308\u20131318 (2020).","journal-title":"Ann. Am. Thorac. Soc."},{"issue":"10048","key":"13207_CR16","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S0140-6736(16)31354-X","volume":"388","author":"D Singh","year":"2016","unstructured":"Singh, D. et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting \u03b22-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet 388 (10048), 963\u2013973 (2016).","journal-title":"Lancet"},{"key":"13207_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.rmed.2019.08.010","volume":"158","author":"KF Rabe","year":"2019","unstructured":"Rabe, K. F. et al. A phase III study of triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler 320\/18\/9.6 \u00b5g and 160\/18\/9.6 \u00b5g using co-suspension delivery technology in moderate-to-very severe COPD: the ETHOS study protocol. Respir Med. 158, 59\u201366 (2019).","journal-title":"Respir Med."},{"key":"13207_CR18","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2147\/COPD.S436326","volume":"19","author":"S Yu","year":"2024","unstructured":"Yu, S., Li, S., Zhang, J. & Fang, Q. Glucocorticoid use in patients hospitalized with chronic obstructive pulmonary disease exacerbations. Int. J. Chron. Obstruct Pulmon Dis. 19, 431\u2013438 (2024).","journal-title":"Int. J. Chron. Obstruct Pulmon Dis."},{"key":"13207_CR19","first-page":"481","volume":"11","author":"D Spyratos","year":"2015","unstructured":"Spyratos, D. & Sichletidis, L. Umeclidinium bromide\/vilanterol combination in the treatment of chronic obstructive pulmonary disease: a review. Ther. Clin. Risk Manag. 11, 481\u2013487 (2015).","journal-title":"Ther. Clin. Risk Manag"},{"issue":"4\u20135","key":"13207_CR20","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1177\/2040622317700822","volume":"8","author":"KS Babu","year":"2017","unstructured":"Babu, K. S. & Morjaria, J. B. Umeclidinium in chronic obstructive pulmonary disease: latest evidence and place in therapy. Ther. Adv. Chronic Dis. 8 (4\u20135), 81\u201391 (2017).","journal-title":"Ther. Adv. Chronic Dis."},{"key":"13207_CR21","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.2147\/COPD.S511593","volume":"20","author":"YJ Huang","year":"2025","unstructured":"Huang, Y. J. et al. Paradigm shift in the treatment of chronic obstructive pulmonary disease improves patient outcomes. Int. J. Chron. Obstruct Pulmon Dis. 20, 1965\u20131972 (2025).","journal-title":"Int. J. Chron. Obstruct Pulmon Dis."},{"issue":"1","key":"13207_CR22","first-page":"52","volume":"12","author":"WC Kwok","year":"2025","unstructured":"Kwok, W. C., Ma, T. F., Tsui, C. K., Ho, J. C. M. & Tam, T. C. C. Prospective randomized study on switching triple inhaler therapy in COPD from multiple inhaler devices to a single inhaler device in a Chinese population. Chronic Obstr. Pulm Dis. 12 (1), 52\u201360 (2025).","journal-title":"Chronic Obstr. Pulm Dis."},{"issue":"5","key":"13207_CR23","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.chest.2024.06.3790","volume":"166","author":"AG Mathioudakis","year":"2024","unstructured":"Mathioudakis, A. G. et al. Rethinking blood eosinophils for assessing inhaled corticosteroids response in COPD: A post hoc analysis from the FLAME trial. Chest 166 (5), 987\u2013997 (2024).","journal-title":"Chest"},{"key":"13207_CR24","doi-asserted-by":"crossref","unstructured":"Agust\u00ed, A. et al. Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. Eur. Respir. J. 61 (4). (2023).","DOI":"10.1183\/13993003.00239-2023"},{"issue":"1","key":"13207_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12931-020-01407-y","volume":"21","author":"A Anzueto","year":"2020","unstructured":"Anzueto, A. & Miravitlles, M. Tiotropium in chronic obstructive pulmonary disease - a review of clinical development. Respir Res. 21 (1), 199 (2020).","journal-title":"Respir Res."},{"issue":"7","key":"13207_CR26","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1164\/rccm.202301-0106PP","volume":"207","author":"A Agust\u00ed","year":"2023","unstructured":"Agust\u00ed, A. et al. Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. Am. J. Respir. Crit Care Med. 207 (7), 819\u2013837 (2023).","journal-title":"Am. J. Respir. Crit Care Med."},{"key":"13207_CR27","doi-asserted-by":"crossref","unstructured":"Loh, L. C. & Ong, C. K. Detailed characterization of hospitalized COPD patients in relation to combined COPD assessment by GOLD. Chronic Obstr. Pulm. Dis. Open. Access. 01 (01). (2017).","DOI":"10.21767\/2572-5548.100004"},{"key":"13207_CR28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2147\/COPD.S427770","volume":"19","author":"KM Beeh","year":"2024","unstructured":"Beeh, K. M., Scheithe, K., Schmutzler, H. & Kr\u00fcger, S. Real-World effectiveness of fluticasone furoate\/umeclidinium\/vilanterol Once-Daily Single-Inhaler triple therapy for symptomatic COPD: the ELLITHE Non-Interventional trial. Int. J. Chron. Obstruct Pulmon Dis. 19, 205\u2013216 (2024).","journal-title":"Int. J. Chron. Obstruct Pulmon Dis."},{"issue":"1","key":"13207_CR29","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12931-019-1193-9","volume":"20","author":"F Maltais","year":"2019","unstructured":"Maltais, F. et al. Efficacy of Umeclidinium\/vilanterol versus Umeclidinium and Salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respir. Res. 20 (1), 238 (2019).","journal-title":"Respir. Res."},{"key":"13207_CR30","doi-asserted-by":"publisher","first-page":"175346662092694","DOI":"10.1177\/1753466620926949","volume":"14","author":"EM Kerwin","year":"2020","unstructured":"Kerwin, E. M. et al. Early and sustained symptom improvement with umeclidinium\/vilanterol versus monotherapy in COPD: a post hoc analysis of the EMAX randomised controlled trial. Ther. Adv. Respir. Dis. 14, 1753466620926949 (2020).","journal-title":"Ther. Adv. Respir. Dis."},{"issue":"9","key":"13207_CR31","doi-asserted-by":"publisher","first-page":"4815","DOI":"10.1007\/s12325-021-01855-y","volume":"38","author":"LH Bjermer","year":"2021","unstructured":"Bjermer, L. H. et al. Efficacy and safety of umeclidinium\/vilanterol in current and former smokers with COPD: A prespecified analysis of the EMAX trial. Adv. Therapy. 38 (9), 4815\u20134835 (2021).","journal-title":"Adv. Therapy"},{"key":"13207_CR32","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.2147\/COPD.S101612","volume":"11","author":"D Singh","year":"2016","unstructured":"Singh, D. et al. Prevention of clinically important deteriorations in COPD with umeclidinium\/vilanterol. Int. J. Chron. Obstruct Pulmon Dis. 11, 1413\u20131424 (2016).","journal-title":"Int. J. Chron. Obstruct Pulmon Dis."},{"key":"13207_CR33","doi-asserted-by":"publisher","first-page":"995","DOI":"10.2147\/COPD.S407238","volume":"18","author":"C Pelaia","year":"2023","unstructured":"Pelaia, C. et al. Clinical and functional effects of inhaled dual therapy umeclidinium\/vilanterol in patients with chronic obstructive pulmonary disease: A Real-Life study. Int. J. Chron. Obstruct Pulmon Dis. 18, 995\u20131002 (2023).","journal-title":"Int. J. Chron. Obstruct Pulmon Dis."},{"key":"13207_CR34","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.2147\/COPD.S252354","volume":"15","author":"T Plate","year":"2020","unstructured":"Plate, T., Friedrich, F. W. & Beier, J. Effectiveness and tolerability of LABA\/LAMA Fixed-Dose combinations aclidinium\/formoterol, glycopyrronium\/indacaterol and umeclidinium\/vilanterol in the treatment of COPD in daily Practice - Results of the Non-Interventional DETECT study. Int. J. Chron. Obstruct Pulmon Dis. 15, 1335\u20131347 (2020).","journal-title":"Int. J. Chron. Obstruct Pulmon Dis."},{"key":"13207_CR35","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2147\/COPD.S479504","volume":"20","author":"A Shaikh","year":"2025","unstructured":"Shaikh, A. et al. Clinical and economic evaluation of fluticasone furoate\/umeclidinium\/vilanterol versus tiotropium\/olodaterol therapy in maintenance Treatment-Naive patients with COPD in the US. Int. J. Chron. Obstruct Pulmon Dis. 20, 335\u2013348 (2025).","journal-title":"Int. J. Chron. Obstruct Pulmon Dis."},{"issue":"12","key":"13207_CR36","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1164\/rccm.201911-2207OC","volume":"201","author":"DA Lipson","year":"2020","unstructured":"Lipson, D. A. et al. Reduction in All-Cause mortality with fluticasone furoate\/umeclidinium\/vilanterol in patients with chronic obstructive pulmonary disease. Am. J. Respir Crit. Care Med. 201 (12), 1508\u20131516 (2020).","journal-title":"Am. J. Respir Crit. Care Med."},{"issue":"1","key":"13207_CR37","first-page":"76","volume":"8","author":"A Bourdin","year":"2021","unstructured":"Bourdin, A. et al. InforMing the pathway of COPD treatment (IMPACT Trial) Single-Inhaler triple therapy (Fluticasone Furoate\/Umeclidinium\/Vilanterol) versus fluticasone furoate\/vilanterol and umeclidinium\/vilanterol in patients with COPD: analysis of the Western Europe and North America regions. Chronic Obstr. Pulm Dis. 8 (1), 76\u201390 (2021).","journal-title":"Chronic Obstr. Pulm Dis."},{"key":"13207_CR38","doi-asserted-by":"publisher","first-page":"995","DOI":"10.2147\/COPD.S407238","volume":"18","author":"C Pelaia","year":"2023","unstructured":"Pelaia, C. et al. Clinical and functional effects of inhaled dual therapy umeclidinium\/vilanterol in patients with chronic obstructive pulmonary disease: A Real-Life study. Int. J. Chronic Obstr. Pulm. Dis. 18, 995\u20131002 (2023).","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13207-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13207-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13207-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T20:37:23Z","timestamp":1763066243000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-13207-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13207"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-13207-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Foshan Hospital of Traditional Chinese (Approval No. FHTCMIRB2025#1025). Informed consent was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"39745"}}